Saudi Consensus Recommendations on the Management of Multiple Sclerosis: Symptom Management and Vaccination

Clinical and Translational Neuroscience Pub Date : 2023-02-03 DOI:10.3390/ctn7010006

Ibtisam A. Al Thubaiti, M. AlKhawajah, Norah Al Fugham, D. Alissa, A. Al-jedai, Y. Al Malik, Mousa A. Almejally, H. Al-Mudaiheem, Bedor A. Al-Omari, Hessa S. Alotaibi, Rumaiza H. Al Yafeai, Mohammed A. Babakkor, R. Bunyan, E. Cupler, Mohammed A. Hakami, Hanaa Kedah, S. Makkawi, Leena H. Saeed, J. Saeedi, E. Shosha, M. A. Al Jumah

{"title":"Saudi Consensus Recommendations on the Management of Multiple Sclerosis: Symptom Management and Vaccination","authors":"Ibtisam A. Al Thubaiti, M. AlKhawajah, Norah Al Fugham, D. Alissa, A. Al-jedai, Y. Al Malik, Mousa A. Almejally, H. Al-Mudaiheem, Bedor A. Al-Omari, Hessa S. Alotaibi, Rumaiza H. Al Yafeai, Mohammed A. Babakkor, R. Bunyan, E. Cupler, Mohammed A. Hakami, Hanaa Kedah, S. Makkawi, Leena H. Saeed, J. Saeedi, E. Shosha, M. A. Al Jumah","doi":"10.3390/ctn7010006","DOIUrl":null,"url":null,"abstract":"This article deals with recommendations on the management of symptoms of MS and on the provision of vaccinations in patients receiving disease-modifying therapies (DMTs). Symptoms of MS, such as fatigue, depression, urinary symptoms, spasticity, impairment of gait, and sexual dysfunction, are common in this population. Recognizing and addressing these symptoms is key to maintaining the quality of life of people with MS. Vaccination status should be reviewed and updated prior to initiation of DMTs. In general, vaccination should be avoided for variable periods after the initiation of some DMTs. Live attenuated vaccines are contraindicated and should be considered on a case-by-case basis. These consensus recommendations will present the best practices for vaccination in Saudi Arabia before, during, and after the COVID-19 pandemic. The recommendations will be updated periodically and as needed as new evidence becomes available.","PeriodicalId":242430,"journal":{"name":"Clinical and Translational Neuroscience","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Neuroscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/ctn7010006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

This article deals with recommendations on the management of symptoms of MS and on the provision of vaccinations in patients receiving disease-modifying therapies (DMTs). Symptoms of MS, such as fatigue, depression, urinary symptoms, spasticity, impairment of gait, and sexual dysfunction, are common in this population. Recognizing and addressing these symptoms is key to maintaining the quality of life of people with MS. Vaccination status should be reviewed and updated prior to initiation of DMTs. In general, vaccination should be avoided for variable periods after the initiation of some DMTs. Live attenuated vaccines are contraindicated and should be considered on a case-by-case basis. These consensus recommendations will present the best practices for vaccination in Saudi Arabia before, during, and after the COVID-19 pandemic. The recommendations will be updated periodically and as needed as new evidence becomes available.

查看原文本刊更多论文

沙特关于多发性硬化管理的共识建议:症状管理和疫苗接种

本文讨论了MS症状的管理建议，以及在接受疾病修饰疗法(dmt)的患者中提供疫苗接种的建议。多发性硬化症的症状，如疲劳、抑郁、泌尿系统症状、痉挛、步态障碍和性功能障碍，在这一人群中很常见。认识和处理这些症状是维持ms患者生活质量的关键，在开始dmt之前应审查和更新疫苗接种状况。一般来说，在某些dmt开始后的不同时期应避免接种疫苗。减毒活疫苗是禁忌症，应根据具体情况进行考虑。这些共识建议将介绍在2019冠状病毒病大流行之前、期间和之后在沙特阿拉伯进行疫苗接种的最佳做法。这些建议将定期更新，并根据需要根据新的证据进行更新。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Translational Neuroscience

自引率

0.00%

发文量